BiotechTube

esomeprazole (Nexium®) + Xolaam®

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

GERD

Conditions

GERD

Trial Timeline

Mar 1, 2007 → Oct 1, 2008

NCT ID
NCT00444275

About esomeprazole (Nexium®) + Xolaam®

esomeprazole (Nexium®) + Xolaam® is a approved stage product being developed by AstraZeneca for GERD. The current trial status is completed. This product is registered under clinical trial identifier NCT00444275. Target conditions include GERD.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00444275ApprovedCompleted

Competing Products

20 competing products in GERD

See all competitors
ProductCompanyStageHype Score
Rabeprazole ER + RanitidineEisaiPhase 3
77
Rabeprazole sodiumEisaiPhase 1
33
Rabeprazole sodium + EsomeprazoleEisaiPhase 3
77
rabeprazole sodium + PlaceboEisaiPhase 3
77
Rabeprazole ER + RanitidineEisaiPhase 3
77
Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mgEisaiPhase 1
33
rabeprazole + rabeprazoleEisaiPhase 3
77
Rabeprazole sodium + EsomeprazoleEisaiPhase 3
77
Rabeprazole sodium + EsomeprazoleEisaiPhase 3
77
ONO-8539Ono PharmaceuticalPhase 1
33
esomeprazole 40 mgJohnson & JohnsonPre-clinical
23
esomeprazoleAstraZenecaPre-clinical
23
EsomeprazoleAstraZenecaApproved
85
EsomeprazoleAstraZenecaApproved
85
esomeprazole magnesiumAstraZenecaPhase 1
33
EsomeprazoleAstraZenecaApproved
85
EsomeprazoleAstraZenecaPhase 3
77
Esomeprazole (Nexium)AstraZenecaApproved
85
OmeprazoleAstraZenecaPhase 3
77
Open Label Run In Esomeprazole + Double Blind Esomeprazole + Double Blind PlaceboAstraZenecaPhase 3
77

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85